OCT imaging has potential as outcome measure for multiple sclerosis

Researchers have demonstrated that quantifying axon thickness in the retinal nerve fiber layer (RNFL) can be reproducibly measured by trained technicians in a multiple sclerosis center using optical coherence tomography (OCT), according to a study published in the September issue of Archives of Neurology.

OCT is a promising new imaging method that has been used predominantly by opthalmologists to monitor glaucoma. It is being considered as a potential outcome measure in multiple sclerosis (MS) clinical trials, but no data exist on the reproducibility of this technique in MS centers, according to background information in the study.

Researchers sought to determine the reproducibility of OCT measurement of mean RNFL thickness in the undilated eyes of healthy control subjects and patients with MS.

“We found excellent agreement with respect to interrater (intraclass correlation [ICC], 0.89), intrarater (ICC, 0.98) and intervisit (ICC, 0.91) results. Mean RNFL thickness did not vary significantly among research centers for patients with MS (93, 92, and 90 µm) or among healthy controls (103, 105 and 104 µm) by site,” the authors wrote.

The findings demonstrated that mean RNFL thickness can be reproducibly measured by trained technicians in an MS center using the OCT-3 model, the authors concluded.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.